Angioimmunoblastic T-Cell Lymphoma (AITL)

Angioimmunoblastic T-cell lymphoma (AITL) is a fast-growing blood cancer of immune cells called T-follicular helper (TFH) cells. These cells normally live in lymph nodes and help B cells make antibodies. In AITL, the TFH cells become cancerous, the lymph nodes enlarge, and the whole immune system becomes overactive and disorganized. This is why many people develop fevers, night sweats, rashes, swollen nodes in many areas, abnormal antibodies in the blood (polyclonal hypergammaglobulinemia), and sometimes autoimmune problems. In modern disease lists, AITL is grouped with other “nodal TFH lymphomas,” reflecting its TFH origin and distinctive markers on the tumor cells. PMC+2jpatholtm.org+2

Angioimmunoblastic T-cell lymphoma (AITL) is a fast-growing cancer of mature T-cells that normally help B-cells in lymph nodes. In the 2022–2025 classifications, AITL is grouped under nodal TFH-cell lymphomas and named nTFHL, angioimmunoblastic-type. Typical signs are swollen lymph nodes in many places, fever, night sweats, weight loss, rash, and immune system problems such as high immunoglobulin levels or autoimmune anemia and low platelets. Many people have Epstein–Barr virus (EBV)–positive B-cells mixed inside the lymph node, which is a feature of this disease. Doctors confirm the diagnosis by removing a lymph node, looking for TFH markers (such as PD-1, CXCL13, ICOS, CD10, BCL6), and doing genetic tests. Common mutations include RHOA G17V, TET2, DNMT3A, and IDH2 (R172). PET-CT scans are used for staging. ASCOPubs+1

Why it happens

Under the microscope, AITL lymph nodes look “busy”: there are many high-endothelial blood vessels, expanded networks of follicular dendritic cells, a mixed set of immune cells, and often many EBV-positive B cells (the cancer cells themselves are T cells, not EBV-infected B cells). Genetic studies commonly find changes in genes that regulate DNA methylation and T-cell signaling—especially TET2 and DNMT3A, often with a hallmark RHOA G17V mutation, and in a subset IDH2 R172. These discoveries explain the strong immune activation and help doctors recognize the disease. DermNet®+2PMC+2

In many patients, early mutations like TET2 and DNMT3A arise in bone-marrow stem cells (clonal hematopoiesis). Later, a RHOA G17V and/or IDH2 R172 mutation in T-cells pushes them toward the TFH type and helps the lymphoma grow. These changes alter DNA regulation and cell signaling. AITL lymph nodes often have many helper T-cells, new blood vessels, and EBV-positive B-cells. EBV is usually in the B-cells (not the tumor T-cells) and can sometimes expand into a separate EBV-positive B-cell lymphoma. Cell+2PMC+2

Other names

• Angioimmunoblastic T-cell lymphoma (AITL) (current common name). PMC

• Nodal T-follicular helper (TFH)–cell lymphoma, angioimmunoblastic-type (WHO 5th edition terminology). Nature+1

• Angioimmunoblastic lymphadenopathy with dysproteinemia and immunoblastic lymphadenopathy (older, pre-lymphoma terms that reflect the immune abnormalities). NCBI

Types

Doctors now think in terms of a family of nodal TFH lymphomas. Within this family are:

1. Angioimmunoblastic-type (the classic pattern described above);

2. Follicular T-cell lymphoma (FTCL), which grows in or around follicles and shares TFH markers; and

3. Nodal TFH cell lymphoma, NOS (not otherwise specified) when cases show TFH features but do not fit cleanly into the other two patterns. Some AITL cases also show prominent EBV-positive B-cell proliferations and can even evolve a secondary EBV-positive B-cell lymphoma. PMC+2SpringerLink+2

Causes

No single cause is proven for most people. Research points to age, immune dysregulation, specific gene mutations, and EBV-positive B cells in the tumor environment as important contributors. Each item below explains a plausible factor in simple terms, with cautious language because “cause” is rarely one-to-one in cancer.

1. Older age – AITL mainly affects people in their 60s–70s; aging immune systems and age-related DNA changes raise risk. PMC

2. Slight male predominance – Rates are a bit higher in men in many series, suggesting sex-linked biology or exposures. PLOS

3. Clonal hematopoiesis genes (TET2, DNMT3A) – Age-related mutations in blood-forming cells can “pre-set” the immune system for later TFH-cell transformation. PMC

4. RHOA G17V mutation – A signature change that alters T-cell signaling and TFH identity; a key step toward lymphoma in many patients. PMC

5. IDH2 R172 mutation (subset) – Further rewires cell metabolism and gene regulation; mostly seen in AITL rather than other TFH lymphomas. ScienceDirect

6. Immune over-activation – TFH tumors drive abnormal antibody production and autoimmune features, which also feed tumor growth. PMC

7. EBV-positive bystander B cells – The tumor micro-environment often contains EBV-infected B cells that can expand and disturb immunity. Oxford Academic

8. Occasional secondary EBV-positive B-cell lymphoma – Rarely, the EBV-positive B cells grow into a second lymphoma alongside AITL. JAAD Case Reports

9. Chronic antigenic stimulation – Ongoing immune triggers (infections, autoimmunity) may keep TFH cells activated for years. (Inference based on TFH biology in reviews.) PMC

10. Genetic cooperation – Combinations like TET2/DNMT3A with RHOA, sometimes with IDH2, appear to cooperate to create cancer. Nature

11. Other mutations (JAK/STAT, VAV1, etc.) – Less common changes can substitute for RHOA/IDH2 in some patients. Modern Pathology

12. Immunosenescence – Aging immunity becomes less precise, making dysregulated TFH and B-cell interactions more likely. (Supported by age distribution data and reviews.) PMC

13. Prior immunosuppression – In a minority, long-term immunosuppressive therapy may alter surveillance and EBV dynamics. (Case-based literature.) Frontiers

14. Environmental factors (uncertain) – Broad lymphoma studies explore smoking, psoriasis, celiac disease, and other associations; evidence is mixed and not AITL-specific. MDPI

15. Ethnic and regional variation – AITL frequency within PTCL varies by geography; reasons are not fully known. PMC

16. Autoimmune background – Autoantibodies and Coombs positivity suggest self-reactive immunity that may both reflect and foster disease. NCBI

17. Polyclonal hypergammaglobulinemia – Overproduction of many antibodies signals persistent TFH-B-cell crosstalk. National Cancer Institute

18. Advanced stage at presentation – Most patients present with stage III/IV disease; while not a cause, widespread immune activation is part of the biology. PLOS

19. Microenvironmental signals – Expanded follicular dendritic cells and high-endothelial venules create a niche that supports tumor cells. DermNet®

20. General lymphoma risk factors – As with many lymphomas, age, male sex, and immunodeficiency states recur as background risks. The Lancet

Symptoms

1. Painless, generalized lymph-node swelling – Nodes in neck, armpits, groin, and elsewhere often enlarge on both sides. National Cancer Institute

2. Fever – Unexplained high temperatures due to cytokine (immune) activation. National Cancer Institute

3. Night sweats – Drenching sweats that soak clothes or sheets. National Cancer Institute

4. Unintentional weight loss – Losing >10% of body weight over months without trying. National Cancer Institute

5. Skin rash – Often widespread, sometimes itchy; reflects immune dysfunction in the skin. DermNet®

6. Fatigue and weakness – From inflammation, anemia, or both. Lymphoma Research Foundation

7. Enlarged spleen and/or liver – Organs of the immune system swell as they fill with reactive and tumor cells. WebPathology

8. Autoimmune problems – Examples: autoimmune hemolytic anemia or immune thrombocytopenia. National Cancer Institute

9. Frequent or unusual infections – AITL causes immune deficiency, so infections may occur more easily. National Cancer Institute

10. Anemia symptoms – Shortness of breath on exertion, paleness, or dizziness if red cells are low. National Cancer Institute

11. Easy bruising or bleeding – If platelets are low because of immune destruction or marrow involvement. National Cancer Institute

12. Swelling from fluid (edema or effusions) – “Leaky” inflamed blood vessels and low proteins can cause leg swelling or fluid around lungs. (Described across case series.) PMC

13. Joint or muscle aches – From systemic inflammation. (Common in inflammatory lymphomas.) PMC

14. Enlarged tonsils or nasal congestion – Part of widespread lymphoid tissue involvement. (General PTCL imaging/ENT experience.) KJR Online

15. Nerve-related symptoms (uncommon) – If the immune process affects nerves, people may notice tingling or weakness. (Reported in broader PTCL context.) KJR Online

Diagnostic tests

A) Physical examination

1. Full lymph-node exam – The doctor feels lymph-node groups (neck, armpit, groin) to map how many areas are affected; AITL usually involves many sites. National Cancer Institute

2. Skin inspection – Looking for rashes or small bruises/petechiae that suggest immune activity or low platelets. DermNet®

3. Abdominal exam – Feeling for an enlarged liver or spleen, common in systemic disease. WebPathology

4. Vital signs and “B symptoms” check – Documenting fever, weight loss, and night sweats helps stage the illness. vicc.org

B) Manual bedside maneuvers

5. Performance status (ECOG/WHO) – A quick, hands-on rating of how illness affects daily activity; it guides decisions and prognosis. (Standard lymphoma practice.) EHA

6. Spleen percussion/palpation – Simple techniques (like Castell’s sign) to screen for splenic enlargement before imaging. (General hematology exam approach.) vicc.org

7. Fluid checks – Bedside assessment for leg pitting edema or signs of pleural/abdominal fluid that fits the inflammatory picture. (Common systemic-lymphoma exam.) vicc.org

C) Laboratory and pathology tests

8. Complete blood count (CBC) with smear – Looks for anemia, low platelets, or abnormal white cells; a baseline for severity. EHA

9. Comprehensive chemistry, LDH, and uric acid – LDH often rises with tumor turnover; chemistry gauges organ function before treatment. EHA

10. Serum protein electrophoresis/immunoglobulins – Many patients have polyclonal hypergammaglobulinemia, a hallmark immune signal in AITL. National Cancer Institute

11. Direct antiglobulin (Coombs) test – Screens for autoimmune hemolysis when anemia is present. NCBI

12. Viral serology and EBV DNA – HIV, hepatitis B/C, and EBV checks guide safety and interpretation; EBV DNA reflects bystander B-cell activity. EHA

13. Autoantibody panel (e.g., ANA, RF) – Supports the pattern of immune dysregulation that is typical in AITL. NCBI

14. Excisional lymph-node biopsy (gold standard) – Entire node removal allows the pathologist to see the classic pattern (many high-endothelial venules, TFH markers) and exclude mimics. Oxford Academic

15. Immunohistochemistry for TFH markers – Tumor cells usually express PD-1, CXCL13, ICOS, often CD10 or BCL6; diagnosis requires multiple TFH markers. jpatholtm.org+1

16. Molecular studies – Testing for T-cell receptor clonality and common mutations (TET2, DNMT3A, RHOA G17V, IDH2 R172) supports and refines the diagnosis. ScienceDirect+1

D) Electrodiagnostic tests

17. Electrocardiogram (ECG) – Not specific for AITL, but important as a baseline in a systemic, older-age cancer where chemotherapy may affect the heart. (Guideline-driven baseline assessment.) EHA

18. Electroencephalogram (EEG) when indicated – If there is confusion, seizures, or suspected CNS involvement, EEG can assess brain function during the work-up. (General oncology practice for neurologic symptoms.) EHA

E) Imaging tests

19. Contrast CT of neck/chest/abdomen/pelvis – Maps disease sites and organ enlargement; widely available and standard in staging. EHA

20. FDG-PET/CT – AITL is typically FDG-avid (lights up on PET). PET/CT improves staging and can reveal extranodal disease that CT alone may miss. PubMed

Non-pharmacological treatments (therapies and “other”)

1. Clinical trials (strongly encouraged).
   Because AITL is uncommon and outcomes with standard therapy are variable, enrolling in a clinical trial can provide access to the newest targeted or combined approaches (for example, adding hypomethylating therapy or novel antibodies to CHOP). Trials also help doctors learn which treatments work best in TFH-type disease. Mechanism: gives you evidence-based, protocol-driven options that may be more precise for TFH biology and EBV-rich microenvironments. Annals of Oncology+1

2. Involved-site radiotherapy (ISRT) for selected sites.
   Radiation is not the main therapy for widespread AITL, but it can be useful for a painful or bulky lymph-node area, or as consolidation after chemotherapy in limited-stage cases. Purpose: reduce symptoms, control local disease, or “mop up” residual activity. Mechanism: high-energy beams damage DNA in lymphoma cells at the targeted site while sparing nearby tissues with modern planning. Annals of Oncology+1

3. Autologous stem cell transplant (ASCT) consolidation in first remission (selected patients).
   For fit patients who achieve remission after frontline therapy, doctors may recommend ASCT to lower relapse risk. Purpose: deepen and prolong remission. Mechanism: give high-dose chemotherapy to eradicate residual disease, then rescue the marrow with your stored stem cells. National Cancer Institute

4. Allogeneic stem cell transplant (allo-SCT) in relapsed/refractory disease.
   For patients who relapse or have high-risk features, allo-SCT can offer the best chance of long-term control. Purpose: cure potential via donor immune effect. Mechanism: donor T-cells can attack residual lymphoma (graft-versus-lymphoma effect) after conditioning therapy. National Cancer Institute

5. Vaccination planning (non-live vaccines).
   Before and after chemotherapy (timing individualized), non-live vaccines such as influenza and pneumococcal are recommended to lower infection risk. Live vaccines are generally avoided during significant immunosuppression. Mechanism: primes the immune system safely when counts allow. Purpose: reduce serious infections while on treatment or post-transplant. PMC+1

6. Fertility and family-planning counseling (before treatment).
   If relevant, meet a fertility specialist quickly. Some chemo can reduce fertility; options include sperm banking or egg/embryo preservation. Purpose: preserve future family options. Mechanism: cryopreservation before cytotoxic therapy. National Cancer Institute

7. Infection-prevention behaviors.
   During chemotherapy, wash hands often, avoid sick contacts, report fever promptly, and follow food-safety steps when neutropenic (for example, careful food handling; in some centers, avoiding probiotic drinks while neutropenic). Purpose: reduce infections. Mechanism: lowers exposure and translocation of germs when white cells are low. Infectious Diseases Society of America+1

8. Exercise and nutrition support.
   Light to moderate activity and a balanced, protein-rich diet can help maintain strength and weight during therapy. A registered dietitian can tailor plans for nausea, taste changes, or diarrhea. Purpose: maintain function and treatment tolerance. Mechanism: supports muscle mass, energy, and immune recovery. PubMed

9. Psychosocial care and symptom management.
   Anxiety, sleep problems, itch, and rash are common. Counseling, support groups, skin care, and palliative-care input improve quality of life and help you stay on therapy. Purpose: better daily wellbeing and adherence. Mechanism: coordinated supportive care for symptoms and stress. NCBI

10. Oral care and dental checks.
    Dental evaluation before chemo and good mouth care during treatment reduce mouth sores and infection risk. Purpose: prevent interruptions in therapy from mucositis or dental infections. Mechanism: addresses dental sources of bacteria and maintains oral hygiene during neutropenia. Infectious Diseases Society of America

---

Drug treatments

Doses below are typical references; your team will personalize them based on age, kidney/liver function, stage, and local guidelines.

1. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) — frontline backbone
   Class & dose/timing: Cyclophosphamide 750 mg/m² IV day 1, doxorubicin 50 mg/m² IV day 1, vincristine 1.4 mg/m² IV day 1 (cap 2 mg), prednisone 100 mg PO days 1–5, every 21 days for 6 cycles, commonly used for AITL. Purpose: induce remission. Mechanism: cytotoxic killing of dividing lymphoma cells. Key side effects: low blood counts, infection, hair loss, neuropathy (vincristine), heart effects (doxorubicin). Cancer Care Ontario+1

2. Brentuximab vedotin + CHP (BV-CHP) — frontline option if CD30-positive
   Class & dose/timing: Anti-CD30 antibody-drug conjugate 1.8 mg/kg IV day 1 plus cyclophosphamide, doxorubicin, prednisone q3 weeks for 6–8 cycles. Purpose: improve outcomes in CD30-expressing PTCL, which can include AITL subsets. Mechanism: delivers a microtubule poison to CD30-positive cells. Side effects: low counts, neuropathy, infusion reactions. PubMed+1

3. Aza-CHOP (oral azacitidine added to CHOP) — TFH-focused strategy (off-label/clinical trials).
   Class & dose/timing: Azacitidine 300 mg PO for 7 days before cycle 1 of CHOP, then 14 days before CHOP cycles 2–6, in trials for TFH-origin lymphomas like AITL. Purpose: boost depth of response in TFH biology. Mechanism: hypomethylating agent may switch on tumor-suppressor genes and sensitize cells to chemo. Side effects: cytopenias, GI upset, fatigue. ASH Publications

4. Belinostat — approved for relapsed/refractory PTCL
   Class & dose/timing: HDAC inhibitor 1,000 mg/m² IV daily on days 1–5 every 21 days until progression/toxicity. Purpose: salvage therapy after relapse. Mechanism: changes gene expression, leading to tumor-cell death. Side effects: fatigue, nausea, low counts, liver test changes. beleodaq.com+1

5. Pralatrexate — approved for relapsed/refractory PTCL
   Class & dose/timing: Antifolate 30 mg/m² IV weekly for 6 weeks in 7-week cycles with folate/B12 support. Purpose: salvage therapy. Mechanism: inhibits folate-dependent DNA synthesis in lymphoma cells. Side effects: mouth sores, low counts, fatigue; folate/B12 reduce mucositis. folotyn.com+1

6. Romidepsin — active in PTCL; U.S. PTCL indication withdrawn but used in practice/regions
   Class & dose/timing: HDAC inhibitor 14 mg/m² IV over 4 h on days 1, 8, 15 every 28 days. Purpose: salvage therapy; sometimes in combinations. Mechanism: epigenetic modulation causing apoptosis. Side effects: low counts, infections, ECG changes; monitoring needed. FDA Access Data

7. Lenalidomide — immunomodulatory agent (off-label in AITL)
   Class & dose/timing: Often 25 mg PO daily on days 1–21 of 28-day cycles in studies. Purpose: salvage, especially for TFH biology. Mechanism: immune modulation and anti-tumor effects. Side effects: cytopenias, rash, blood clots (consider anticoagulation per risk). PubMed+1

8. Duvelisib — PI3K-δ/γ inhibitor (off-label/clinical trials for PTCL)
   Class & dose/timing: Dose-optimized schedules used in trials (e.g., 75 mg BID for 2 cycles then 25 mg BID); protocols vary. Purpose: salvage therapy. Mechanism: blocks PI3K pathways important in T-cell signaling. Side effects: infections, diarrhea/colitis, pneumonia—requires close monitoring. PMC+1

9. Bendamustine (often in combinations).
   Class & dose/timing: Alkylator 90–120 mg/m² IV days 1–2 q21–28 days (varies by regimen). Purpose: salvage therapy, sometimes with brentuximab or rituximab depending on biology. Mechanism: DNA crosslinking cytotoxic. Side effects: cytopenias, infection risk. PMC+1

10. Gemcitabine-based regimens (e.g., GDP, GemOx).
    Class & dose/timing: Example GDP schedules use gemcitabine with dexamethasone + cisplatin as salvage. Purpose: disease control and bridge to transplant. Mechanism: nucleoside analog damaging DNA. Side effects: low counts, fatigue, kidney considerations (cisplatin). eviQ+1

Notes your team may discuss: Rituximab can be added when there is a significant EBV-positive B-cell component, aiming to reduce that clone; evidence is mixed and individualized. Some AITL cases express CD30, making BV-CHP attractive upfront. Consolidation with ASCT in first remission and allo-SCT for relapse are guideline-supported in selected patients. PMC+2PubMed+2

---

Dietary molecular supplements

Important: No supplement has been proven to treat AITL. Discuss every product with your oncologist. High-dose antioxidants during active chemo or radiation may interfere with treatment; use great caution. National Cancer Institute+1

1. Vitamin D (if deficient).
   Vitamin D helps bone and immune health. Doctors often check levels and replace if low. Typical replacement doses vary (e.g., daily 800–2,000 IU or weekly prescription dosing), guided by blood tests. Function/mechanism: supports calcium balance and immune function; deficiency is common in cancer. Evidence does not show it treats AITL. PubMed

2. Omega-3 fatty acids (fish oil) for nutrition support.
   Omega-3s may help maintain weight and reduce inflammation-related symptoms for some patients, but can increase bleeding risk, so dosing must be individualized. Mechanism: membrane and anti-inflammatory effects; supportive only. PubMed

3. Oral protein supplements (whey/plant) if intake is poor.
   If appetite is low, a protein shake can help meet daily protein goals to maintain muscle. Dosing depends on needs (e.g., 20–30 g protein per serving). Mechanism: supports recovery and resilience during chemotherapy. PubMed

4. Electrolyte solutions during diarrhea/vomiting.
   Medically formulated oral rehydration solutions can prevent dehydration when GI side effects hit. Mechanism: replaces water and salts in the right ratios. Not a treatment for lymphoma. PubMed

5. Probiotics — only with oncology approval.
   Data are mixed. Some trials show benefit for treatment-related diarrhea, but case reports raise safety questions in severe neutropenia. Many centers advise avoiding probiotic supplements during profound neutropenia; fermented foods are often discouraged at those times. Always ask your team first. Lippincott Journals+2ScienceDirect+2

---

Immunity-booster / regenerative / stem-cell support drugs

1. Filgrastim or pegfilgrastim (G-CSF).
   Purpose: reduce the duration of chemotherapy-induced neutropenia and febrile neutropenia risk. Mechanism: stimulates the bone marrow to make neutrophils. Dosing: daily filgrastim or one-time per cycle pegfilgrastim per guideline risk. Side effects: bone pain. PMC

2. IVIG (intravenous immunoglobulin) — selected patients.
   Purpose: if you have severe, recurrent infections with low IgG levels, IVIG can lower infection risk. Mechanism: replaces missing antibodies. Side effects: headache, infusion reactions; used only when clearly indicated. Infectious Diseases Society of America

3. Antimicrobial prophylaxis (per risk).
   Purpose: prevent infections during periods of high risk (e.g., TMP-SMX for Pneumocystis, acyclovir for HSV/VZV, antifungals in prolonged neutropenia). Mechanism: lowers specific opportunistic infections. Side effects: drug-specific. Decisions are individualized using ASCO/IDSA guidance. Infectious Diseases Society of America

---

Key procedures / surgeries you may encounter

1. Excisional lymph-node biopsy.
   This minor surgery removes a whole node to allow a full pathologic and genetic work-up. It is the gold standard to diagnose AITL and to avoid sampling error.

2. Central venous access (port or PICC).
   A small procedure to place a line for safe, repeated chemotherapy and blood draws. It helps protect veins and ensures reliable access. National Cancer Institute

3. Splenectomy (rare, selected cases).
   Occasionally considered for severe hypersplenism (very large spleen destroying blood cells) not controlled by other measures. It is not standard for treating AITL itself. National Cancer Institute

---

 Practical prevention tips

There is no proven way to prevent AITL from developing. These tips help prevent complications during/after treatment:

1. Get non-live vaccines at recommended times (influenza, COVID-19, pneumococcal), coordinated with your oncology team. PMC+1

2. Follow fever-neutropenia plans: call urgently for fever and start antibiotics per your team’s advice. Infectious Diseases Society of America

3. Use G-CSF when your regimen and risk meet guideline thresholds. PMC

4. Practice food and hand hygiene, and avoid sick contacts when counts are low. Infectious Diseases Society of America

5. Maintain balanced nutrition and physical activity as tolerated. PubMed

6. Avoid high-dose antioxidant supplements during active chemo/radiation unless your oncologist says otherwise. National Cancer Institute

7. Discuss fertility preservation before therapy if relevant. National Cancer Institute

8. Keep dental care up-to-date to lower infection risk. Infectious Diseases Society of America

9. Ask about antiviral/antifungal/PJP prophylaxis if your regimen is high-risk. Infectious Diseases Society of America

10. Consider clinical trials whenever available. Annals of Oncology

---

When to see (or call) a doctor urgently

Call immediately for fever (commonly ≥38.0–38.3 °C), chills, shortness of breath, chest pain, confusion, uncontrolled vomiting or diarrhea, bleeding, or new severe pain or rash. Fever with low neutrophils is an emergency and needs same-day assessment and antibiotics. Lymphoma Research Foundation+1

---

What to eat — and what to avoid

Eat: small, frequent, balanced meals with lean proteins, fruits/vegetables that are well-washed/cooked when neutropenic, whole grains, and adequate fluids. A registered dietitian can tailor plans for nausea, taste changes, or weight loss. PubMed

Avoid or limit: alcohol excess; undercooked meats/eggs; unpasteurized dairy; raw sprouts; and—during periods of severe neutropenia—yogurts or drinks labeled probiotic unless your team says they’re safe. Be cautious with supplements, especially high-dose antioxidants or herbal products that may interact with chemo. Blood Cancer UK+1

---

FAQs

1. Is AITL the same as nTFHL-AITL?
   Yes. Modern classifications call it nodal TFH cell lymphoma, angioimmunoblastic-type.

2. Is it common?
   No. It’s a rare peripheral T-cell lymphoma. National Cancer Institute

3. What causes it?
   A mix of genetic changes in TFH-type T-cells (RHOA/TET2/DNMT3A/IDH2) and a permissive microenvironment with EBV-positive B-cells. Modern Pathology+1

4. How is it found?
   Excisional lymph-node biopsy with special stains and genetic studies; PET-CT stages the body. Annals of Oncology

5. Does EBV cause AITL?
   EBV is usually present in bystander B-cells and may expand; its exact role in causing AITL is complex and indirect. PMC

6. What is first-line treatment?
   Often CHOP. If the tumor expresses CD30, BV-CHP is a key option. Some centers add oral azacitidine to CHOP in TFH-type disease within trials. Cancer Care Ontario+2PubMed+2

7. Will I need a transplant?
   Fit patients may be offered ASCT consolidation in first remission; allo-SCT is often considered if disease returns. National Cancer Institute

8. What if it comes back?
   Options include belinostat, pralatrexate, romidepsin, lenalidomide, duvelisib, bendamustine or gemcitabine-based regimens, and clinical trials. FDA Access Data+2folotyn.com+2

9. Are there targeted drugs?
   Some therapies target surface markers (e.g., CD30) or pathways (PI3K), or use epigenetic drugs (HDAC inhibitors/hypomethylating agents). PubMed+1

10. Can rituximab help?
    Sometimes used when there’s a large EBV-positive B-cell component to reduce that clone; decisions are individualized. PMC

11. Do supplements cure AITL?
    No. Use supplements only to correct deficiencies or support nutrition, and always clear them with your team. Avoid high-dose antioxidants during active chemo/radiation. National Cancer Institute

12. Should I get vaccines?
    Yes, non-live vaccines are recommended with careful timing; live vaccines are generally avoided during immunosuppression. PMC+1

13. What’s the role of PET-CT?
    It helps with staging and response assessment and is recommended in PTCL work-ups. Annals of Oncology

14. Why do I have a rash?
    Skin rashes are common in AITL due to immune dysregulation and cytokines; dermatology support can help symptom control. NCBI

15. When should I call urgently?
    Fever ≥38–38.3 °C, shaking chills, breathing trouble, uncontrolled vomiting/diarrhea, heavy bleeding, confusion, or new severe pain. Fever with low neutrophils is an emergency. Lymphoma Research Foundation+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 17, 2025.